| Laura M Henry, CRNA | |
|
905 Kinley Avenue Nw, Albuquerque, NM 87104 | |
| (505) 242-2400 | |
| Not Available |
| Full Name | Laura M Henry |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 18 Years |
| Location | 905 Kinley Avenue Nw, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083754519 | NPI | - | NPPES |
| 591-91294 | Other | AL | BLUE CROSS BLUE SHIELD |
| G4164 | Other | FL | BLUE CROSS BLUE SHIELD |
| 009941156 | Medicaid | AL | |
| 308160500 | Medicaid | FL | |
| P00380939 | Other | FL | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | ARNP9163037 (Florida) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | CRNA-01261 (New Mexico) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Partners And Management Llc | 9931429198 | 133 |
News Archive
StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.
Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.
The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007. In total, 2503 proposals were submitted to the second Starting Grant call.
Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.
When these cardiovascular risk factors led to a fatal heart attack or stroke in people who had not had a previous heart attack or stroke, it cost more than $13 billion in hospitalization and lost wages annually.
› Verified 5 days ago
| Entity Name | Anesthesia Partners & Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336530997 PECOS PAC ID: 9931429198 Enrollment ID: O20150529000706 |
News Archive
StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.
Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.
The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007. In total, 2503 proposals were submitted to the second Starting Grant call.
Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.
When these cardiovascular risk factors led to a fatal heart attack or stroke in people who had not had a previous heart attack or stroke, it cost more than $13 billion in hospitalization and lost wages annually.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura M Henry, CRNA 905 Kinley Avenue Nw, Albuquerque, NM 87104 Ph: (505) 242-2400 | Laura M Henry, CRNA 905 Kinley Avenue Nw, Albuquerque, NM 87104 Ph: (505) 242-2400 |
News Archive
StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.
Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.
The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007. In total, 2503 proposals were submitted to the second Starting Grant call.
Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.
When these cardiovascular risk factors led to a fatal heart attack or stroke in people who had not had a previous heart attack or stroke, it cost more than $13 billion in hospitalization and lost wages annually.
› Verified 5 days ago
Francis Joseph Stoecker Iii, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1313 Dakota St Se, Albuquerque, NM 87108 Phone: 719-351-7921 | |
Kyle Rodgers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 6709 Academy Rd Ne Ste A, Albuquerque, NM 87109 Phone: 505-308-3145 | |
Mr. J D Sharick, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2211 Lomas Blvd Ne, Albuquerque, NM 87106 Phone: 505-272-3119 | |
Hideyo Tsumura, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4401 Masthead St Ne Ste 120, Albuquerque, NM 87109 Phone: 505-243-7729 Fax: 505-243-4804 | |
Mr. Michael Bailey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7788 Jefferson St Ne, Albuquerque, NM 87109 Phone: 505-999-1600 Fax: 505-999-1650 | |
David Vincent Dick, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1100 Central Ave Se, Albuquerque, NM 87106 Phone: 505-841-1234 Fax: 505-841-1956 | |
Morgan J Ouellette Morrow, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1100 Central Ave Se, Albuquerque, NM 87106 Phone: 505-841-1234 Fax: 505-841-1956 |